ZEMBRACE SYMTOUCH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEMBRACE SYMTOUCH (ZEMBRACE SYMTOUCH).
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibition of trigeminal nerve transmission.
| Metabolism | Primarily metabolized by monoamine oxidase A (MAO-A) to an inactive indole acetic acid metabolite; minor metabolism by CYP450 enzymes. |
| Excretion | Primarily renal (approximately 80–90% as unchanged drug); fecal elimination is minor (<10%). |
| Half-life | Terminal elimination half-life is approximately 2.5 hours (range 2–3 hours) in healthy adults; prolonged in renal impairment. |
| Protein binding | Approximately 14% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Approximately 7.1 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Subcutaneous: 100% (absolute bioavailability via SC injection due to complete absorption). |
| Onset of Action | Subcutaneous injection: clinical effect observed within 2.5–3.5 hours post-dose. |
| Duration of Action | Duration of action is approximately 24 hours based on once-daily dosing; triptan effects may persist up to 24 hours. |
| Molecular Weight | Galcanezumab is a humanized monoclonal antibody; approximate molecular weight is 150 kDa (150,000 Da). |
Subcutaneous administration of 140 mg/mL, 1 mL (140 mg) once daily, or 140 mg/mL, 2 mL (280 mg) once every 2 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients aged ≥65 years, no overall differences in safety or efficacy observed. |
| 1st trimester | Avoid in first trimester unless benefit outweighs risk; may cause fetal harm based on mechanism of action (CGRP receptor antagonist) and animal studies showing embryo-fetal toxicity. |
| 2nd trimester | Use only if clearly needed; no adequate human studies, but potential for fetal harm due to placental transfer of monoclonal antibodies increasing as gestation progresses. |
| 3rd trimester | Not recommended in third trimester due to potential for fetal harm and unknown effects on neonatal hemostasis (monoclonal antibodies cross placenta more readily after 20 weeks). |
Clinical note
Comprehensive clinical and safety monograph for ZEMBRACE SYMTOUCH (ZEMBRACE SYMTOUCH).
| Placental transfer | As a monoclonal antibody (IgG), galcanezumab is likely to cross the placenta, with transfer increasing as pregnancy progresses, especially after the first trimester. |
| Breastfeeding | It is unknown if galcanezumab is excreted in human milk; however, human IgG is present in breast milk, and systemic absorption of monoclonal antibodies from breast milk is expected to be low due to limited gastrointestinal absorption in infants. Caution should be exercised with maternal use. |
■ FDA Black Box Warning
Sumatriptan is contraindicated in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular disease due to risk of myocardial ischemia, infarction, and stroke.
| Serious Effects |
Hypersensitivity to galcanezumab or any excipientsHistory of allergic reactions to monoclonal antibodies
| Precautions | Risk of myocardial ischemia, infarction, and arrhythmias, Cerebral and peripheral vascular events including stroke, Increased blood pressure, Serotonin syndrome, especially with concurrent serotonergic drugs, Medication overuse headache, Severe anaphylactic reactions, Ocular effects including angle-closure glaucoma, Use with caution in patients with hepatic impairment |
| Food/Dietary | No significant food interactions. Should be injected on an empty stomach for consistent absorption, but not required. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | ZEMBRACE SYMTOUCH (sumatriptan succinate) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, sumatriptan was associated with increased incidences of fetal malformations (including craniofacial and cardiovascular defects) and embryolethality at doses approximately 40 times the maximum recommended human dose. However, the relevance to human pregnancy is uncertain. First trimester exposure: Data from pregnancy registries and observational studies do not consistently suggest a major increase in the risk of birth defects, but a small increase in the risk of major congenital malformations cannot be excluded. Second and third trimesters: Potential for decreased uterine blood flow leading to fetal hypoxia; use only if potential benefit justifies potential risk. |
| Fetal Monitoring | Monitor for signs of uterine hyperstimulation or decreased fetal heart rate variability due to potential vasoconstriction of uterine arteries. Assess fetal well-being by ultrasound and nonstress test as clinically indicated. Monitor maternal blood pressure and heart rate. In patients with cardiovascular risk factors, consider electrocardiogram monitoring. Observe for symptoms of serotonin syndrome when used with other serotonergic drugs. |
| Fertility Effects | There are no adequate data on the effect of sumatriptan on human fertility. In animal fertility studies, sumatriptan at doses up to 300-fold the human exposure did not impair fertility, but delayed implantation and reduced embryo survival were observed. The clinical relevance is unknown. |
| Clinical Pearls | ZEMBRACE SYMTOUCH (sumatriptan succinate) is a self-administered subcutaneous injection for acute migraine treatment. The auto-injector delivers a single 3 mg dose (0.5 mL) subcutaneously, typically in the thigh or abdomen. Onset of action is rapid, within 10 minutes. Avoid use within 24 hours of other 5-HT1 agonists or ergotamines. Contraindicated in patients with ischemic heart disease, prior MI, uncontrolled hypertension, hemiplegic or basilar migraine. Do not give IV due to coronary vasospasm risk. Maximum dose in 24 hours is two injections (6 mg). Most common adverse effects are injection site reactions, tingling, dizziness, and warm/hot sensation. |
| Patient Advice | Use the auto-injector exactly as prescribed at the first sign of migraine headache. · Do not use more than two injections in 24 hours, with at least 1 hour between doses. · Inject subcutaneously into the thigh or abdomen; avoid injection into a vein or muscle. · Rotate injection sites to minimize skin reactions. · Seek emergency care if you experience chest pain, shortness of breath, irregular heartbeat, or severe abdominal pain. · Do not use within 24 hours of other migraine medications containing triptans or ergotamines. · Avoid driving or operating machinery until you know how the medication affects you. · Store the auto-injector at room temperature away from light and moisture. |